ArticleAmerican journal of translational research2026
Association of immune-related gene DNA methylation patterns with tumor progression in colorectal cancer: a clinical translational study.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the prognostic value and clinical use of plasma-derived immune gene DNA methylation patterns in colorectal cancer (CRC).
methodsA total of 300 patients with pathologically confirmed CRC (2021-2023) and 100 healthy controls were retrospectively enrolled. Methylation levels of programmed death-ligand 1 (PD-L1), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), interferon regulatory factor 1 (IRF1), and forkhead box protein P3 (FOXP3) were measured using methylation-specific quantitative polymerase chain reaction (MSP). An integrated methylation risk score (IMRS) was developed using a logistic regression model. The associations between IMRS and clinicopathologic characteristics were analyzed. All patients were followed up for 24 months postoperatively. The prognostic performances of IMRS and carcinoembryonic antigen (CEA) for recurrence-free survival (RFS) were evaluated and compared using Kaplan-Meier and Cox regression analyses.
resultsCRC patients exhibited a markedly elevated IMRS compared to controls (
conclusionsThe IMRS, derived from circulating immune gene methylation, independently predicts aggressive clinicopathological features and unfavorable prognosis in CRC, highlighting its potential as a noninvasive biomarker for postoperative risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.